Dopamine d2 Receptor Antikörper (AA 214-373)
Kurzübersicht für Dopamine d2 Receptor Antikörper (AA 214-373) (ABIN6139821)
Target
Alle Dopamine d2 Receptor (DRD2) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 214-373
-
Sequenz
- IVLRRRRKRV NTKRSSRAFR AHLRAPLKGN CTHPEDMKLC TVIMKSNGSF PVNRRRVEAA RRAQELEMEM LSSTSPPERT RYSPIPPSHH QLTLPDPSHH GLHSTPDSPA KPEKNGHAKD HPKIAKIFEI QTMPNGKTRT SLKTMSRRKL SQQKEKKATQ
-
Kreuzreaktivität
- Human, Maus, Ratte
-
Produktmerkmale
- Polyclonal Antibodies
-
Aufreinigung
- Affinity purification
-
Immunogen
- Recombinant fusion protein containing a sequence corresponding to amino acids 214-373 of human DRD2 (NP_000786.1).
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- WB,1:500 - 1:1000
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- Dopamine d2 Receptor (DRD2) (Dopamine Receptor D2 (DRD2))
-
Andere Bezeichnung
- DRD2
-
Hintergrund
- This gene encodes the D2 subtype of the dopamine receptor. This G-protein coupled receptor inhibits adenylyl cyclase activity. A missense mutation in this gene causes myoclonus dystonia, other mutations have been associated with schizophrenia. Alternative splicing of this gene results in two transcript variants encoding different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing.,DRD2,D2DR,D2R,Signal Transduction,G protein signaling,G-Protein-Coupled Receptors(GPCR),Neuroscience,Cell Type Marker,Neurodegenerative Diseases,Dopamine Signaling in Parkinson's Disease,Neuron marker,Dendrite marker,DRD2
-
Molekulargewicht
- 47 kDa/50 kDa
-
Gen-ID
- 1813
-
UniProt
- P14416
-
Pathways
- Positive Regulation of Peptide Hormone Secretion, Negative Regulation of Hormone Secretion, cAMP Metabolic Process, Inositol Metabolic Process, Regulation of G-Protein Coupled Receptor Protein Signaling, Feeding Behaviour, Negative Regulation of Transporter Activity, Regulation of long-term Neuronal Synaptic Plasticity
Target
-